CDK14 and Parkinson disease: Genetic reduction of CDK14 using a CRISPR/Cas9-mediated strategy in stem cell-derived human neurons carrying the PD-linked SNCA A53T mutation lowered levels of pS129 α-Syn (Fig. 3), indicating that ablation of both, murine and human Cdk14/CDK14 mitigates the neuronal load of this pathology-linked form of α-Syn.